Newsroom Subscribe Contact
About us
About us
Our Science
Our Science
Pipeline
Pipeline
Investors
Investors

Novel small molecules
for mental health indications

Enveric has a robust pipeline of development programs targeting unmet needs in anxiety, depression and/or addiction disorders.
pills 1

Development Programs

EVM201 Series
EB-373
Generalized Anxiety Disorder
EVM301 Series
Undisclosed
Undisclosed Indication
Discovery
Preclinical
Phase 1
Phase 2

Anxiety Disorders

Anxiety Continues to be a Large Unmet Need with Limited Innovative Treatments

  • Anxiety disorders are the second most common central nervous system disorders
  • Persons living with anxiety disorders experience the ailments and debilitating effects of chronic conditions, affecting their quality of life.
Watch The Film

Percent of Adults Ages 18-64 in the General Population Who Meet Diagnostic Criteria for Anxiety Disorders in the Past Year and in Their Lifetime

Anxiety Disorder
Specific Phobia
Social Anxiety Disorder
Panic Disorder
Agoraphobia
Generalized Anxiety Disorder
12-Month Prevalence
Total
10.1
8.0
3.1
1.7
2.9
Lifetime Prevalence
Total
13.8
13
5.2
2.6
6.2

Limitations of Current Anxiety Pharmacologic Treatments

Anxiolytics

Key Limitations
Limited Efficacy
Safety & Tolerability Issues
Risk of Abuse & DependenceBZD
  • Limited efficacy with significant number of patients with residual untreated symptoms.
  • Safety and tolerability issues, including GI upset, sexual dysfunction, serotonin toxicity, and more.
  • Risk of abuse and dependence, particularly with the chronic use of benzodiazepines.

1st Gen Psilocybin

Key Limitations
Slow Onset of Action
Prolonged Psychedelic “Trip”
Safety & Tolerability Issues
  • Effectiveness not confirmed (currently under investigation)
  • Challenges with patentability
  • Anecdotal evidence in the absence of rigorous investigations
  • Safety and tolerability issues

Potential Expansion Indications

Novel Treatment Paradigm

  • Optimized treatment regimen for quick, profound and lasting behavioral changes.
  • Monotherapy and/or adjunctive therapy as Single Administration (SA) with Individualized Repeat Dosing (IRD) for a Precision Medicine approach to tailor individual patient needs.
  • Drug administration inside a clinical setting (under minimal supervision of a health care professional) or outside a clinical setting (provided it is deemed safe to do so).

Discovering Next-generation Treatments for Mental Illness

Leadership Team
About Enveric
Our mission is to pioneer a paradigm shift and generate new solutions with the potential to have profound effects on patients and their families, and to deliver life-changing medicines for diseases affecting the brain, such as anxiety, depression, and addiction.